[
  {
    "ts": null,
    "headline": "‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology",
    "summary": "\"The winners in life are differentiated from the losers in life because the winners never fall,\" Albert Bourla says. \"The winners always stand up again.\"",
    "url": "https://finnhub.io/api/news?id=aea83cd55131bde5831cf473000bf6a9dec3926faff6cc833d637c49da1c122e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769797331,
      "headline": "‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology",
      "id": 138310322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "\"The winners in life are differentiated from the losers in life because the winners never fall,\" Albert Bourla says. \"The winners always stand up again.\"",
      "url": "https://finnhub.io/api/news?id=aea83cd55131bde5831cf473000bf6a9dec3926faff6cc833d637c49da1c122e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push",
    "summary": "WASHINGTON, Jan 30 (Reuters) - Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and",
    "url": "https://finnhub.io/api/news?id=f4cc3bed64f6c4a0b48fb92cbb60541c7a7beff7f75cbc7fbb6460fdb65cd68c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769789304,
      "headline": "Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push",
      "id": 138307273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "WASHINGTON, Jan 30 (Reuters) - Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and",
      "url": "https://finnhub.io/api/news?id=f4cc3bed64f6c4a0b48fb92cbb60541c7a7beff7f75cbc7fbb6460fdb65cd68c"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=b329f09d49bf2f45733f7c72050cdd0ecb93df785af997b372e3cf6e8e5871d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769781604,
      "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
      "id": 138306231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=b329f09d49bf2f45733f7c72050cdd0ecb93df785af997b372e3cf6e8e5871d4"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Roundup: Big Name Earnings",
    "summary": "Large cap tech earnings. Health insurance stocks drop. Good news in travel and leisure. Interesting new Fed Chair.",
    "url": "https://finnhub.io/api/news?id=760a48a16e5d38ec85c69d461827e030e5d63090e3f0b10f0e85d38541fb28f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769781000,
      "headline": "Wall Street Roundup: Big Name Earnings",
      "id": 138308182,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252783461/image_2252783461.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Large cap tech earnings. Health insurance stocks drop. Good news in travel and leisure. Interesting new Fed Chair.",
      "url": "https://finnhub.io/api/news?id=760a48a16e5d38ec85c69d461827e030e5d63090e3f0b10f0e85d38541fb28f9"
    }
  },
  {
    "ts": null,
    "headline": "Will BMY's Oncology Collaborations Drive Its Next Growth Phase?",
    "summary": "BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.",
    "url": "https://finnhub.io/api/news?id=6d3235feb7809fc118260c3964811cf411a3585c4a22acc128c5826ccb345911",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769780940,
      "headline": "Will BMY's Oncology Collaborations Drive Its Next Growth Phase?",
      "id": 138306066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.",
      "url": "https://finnhub.io/api/news?id=6d3235feb7809fc118260c3964811cf411a3585c4a22acc128c5826ccb345911"
    }
  },
  {
    "ts": null,
    "headline": "CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?",
    "summary": "CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.",
    "url": "https://finnhub.io/api/news?id=fd9d8ace6873a18129fe49cc329795265f5e74d5a25a8a09e49f7404edf6a188",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769780340,
      "headline": "CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?",
      "id": 138306233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.",
      "url": "https://finnhub.io/api/news?id=fd9d8ace6873a18129fe49cc329795265f5e74d5a25a8a09e49f7404edf6a188"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?",
    "summary": "PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates weigh on the outlook",
    "url": "https://finnhub.io/api/news?id=2bf54117d341332786bdeb237da15d99da041ffd58c2d5d47a8d3b6842329ce0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769777880,
      "headline": "Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?",
      "id": 138306234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates weigh on the outlook",
      "url": "https://finnhub.io/api/news?id=2bf54117d341332786bdeb237da15d99da041ffd58c2d5d47a8d3b6842329ce0"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings",
    "summary": "Merck heads into Q4 earnings with strong Keytruda demand and new product launches, but declining estimates and M&A costs cloud the near-term outlook.",
    "url": "https://finnhub.io/api/news?id=bd9854ddab8b151df0e9dd202975f68875de5e626bc8fdacf7688d03476383cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769777400,
      "headline": "Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings",
      "id": 138306183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck heads into Q4 earnings with strong Keytruda demand and new product launches, but declining estimates and M&A costs cloud the near-term outlook.",
      "url": "https://finnhub.io/api/news?id=bd9854ddab8b151df0e9dd202975f68875de5e626bc8fdacf7688d03476383cd"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year",
    "summary": "All three can provide you with solid, consistent income.",
    "url": "https://finnhub.io/api/news?id=50c5240230cbb28fe77da703a80528db5975c8c2cb5b075bf63d4c67f2b1d7d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769775600,
      "headline": "3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year",
      "id": 138305409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All three can provide you with solid, consistent income.",
      "url": "https://finnhub.io/api/news?id=50c5240230cbb28fe77da703a80528db5975c8c2cb5b075bf63d4c67f2b1d7d6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Buyer Beware, The Risk Outweighs The Reward",
    "summary": "Pfizer: Buyer Beware, The Risk Outweighs The Reward",
    "url": "https://finnhub.io/api/news?id=57cc789c9f0aba96fadfdd01c660cb0963a86638315f4514da5c5e22e57cde43",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769769081,
      "headline": "Pfizer: Buyer Beware, The Risk Outweighs The Reward",
      "id": 138305975,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=57cc789c9f0aba96fadfdd01c660cb0963a86638315f4514da5c5e22e57cde43"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China’s CSPC",
    "summary": "The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.",
    "url": "https://finnhub.io/api/news?id=f0af40e3cc3f1ab2971987129d9ea8270164e65e0910fad15a0808499dc3c0bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769759460,
      "headline": "AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China’s CSPC",
      "id": 138304027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.",
      "url": "https://finnhub.io/api/news?id=f0af40e3cc3f1ab2971987129d9ea8270164e65e0910fad15a0808499dc3c0bf"
    }
  },
  {
    "ts": null,
    "headline": "Why Dividend Stocks Are Essential For What Comes Next",
    "summary": "High-quality dividend stocks like OKE, PFE, and CAG gain as low rates and OKE's 5.6% yield drive upside. Find out why SCHD and value plays offer 2026 growth.",
    "url": "https://finnhub.io/api/news?id=d14019912383ddf146a3820879a00cef930e62688d21dfbb1a03b4cbc3d6c786",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769758200,
      "headline": "Why Dividend Stocks Are Essential For What Comes Next",
      "id": 138304852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1050058124/image_1050058124.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "High-quality dividend stocks like OKE, PFE, and CAG gain as low rates and OKE's 5.6% yield drive upside. Find out why SCHD and value plays offer 2026 growth.",
      "url": "https://finnhub.io/api/news?id=d14019912383ddf146a3820879a00cef930e62688d21dfbb1a03b4cbc3d6c786"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19",
    "summary": "Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.",
    "url": "https://finnhub.io/api/news?id=be9d69e5e1ea58836e6eb487452344f8265c55c45e50eadf61f8b85e423194ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769732760,
      "headline": "Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19",
      "id": 138302563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.",
      "url": "https://finnhub.io/api/news?id=be9d69e5e1ea58836e6eb487452344f8265c55c45e50eadf61f8b85e423194ef"
    }
  }
]